Chunhe Wang

Dr. Chunhe Wang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2021 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
YCYuning Chen
Yuning Chen
YZYa-Nan Zhang
Ya-Nan Zhang
RYRenhong Yan
Renhong Yan
GWGuifeng Wang
Guifeng Wang
YZYuanyuan Zhang
Yuanyuan Zhang
CWChunhe Wang
Chunhe Wang
The evolution of coronaviruses, such as SARS-CoV-2, makes broad-spectrum coronavirus preventional or therapeutical strategies highly sought after. Here we report a human angiotensin-converting enzyme 2 (ACE2)-targeting monoclonal antibody, 3E8, blocked the S1-subunits and pseudo-typed virus constructs from multiple coronaviruses including SARS-CoV-2, SARS-CoV-2 mutant variants (SARS-CoV-2-D614G, B.1.1.7, B.1.351, B.1.617.1, and P.1), SARS-CoV and HCoV-NL63, without markedly affecting the physiological activities of ACE2 or causing severe toxicity in ACE2 “knock-in” mice. 3E8 also blocked live SARS-CoV-2 infection in vitro and in a prophylactic mouse model of COVID-19. Cryo-EM and “alanine walk” studies revealed the key binding residues on ACE2 interacting with the CDR3 domain of 3E8 heavy chain. Although full evaluation of safety in non-human primates is necessary before clinical development of 3E8, we provided a potentially potent and “broad-spectrum” management strategy against all coronaviruses that utilize ACE2 as entry receptors and disclosed an anti-coronavirus epitope on human ACE2.

29 July 2020 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
TSTing Shao
Ting Shao
TCTianzhi Chen
Tianzhi Chen
YCYuning Chen
Yuning Chen
XLXiaoyue Liu
Xiaoyue Liu
YCYi-Li Chen
Yi-Li Chen
CWChunhe Wang
Chunhe Wang

6 May 2022 in Clinical and Translational Medicine
Verified
Journal Article
Open access
SMSonglin Mu
Songlin Mu
ZLZhijuan Liang
Zhijuan Liang
YWYongmei Wang
Yongmei Wang
WCWendi Chu
Wendi Chu
YCYi‐Li Chen
Yi‐Li Chen
CWChunhe Wang
Chunhe Wang

20 January 2025 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
JLJing Long
Jing Long
TSTing Shao
Ting Shao
YWYongmei Wang
Yongmei Wang
TCTianzhi Chen
Tianzhi Chen
YCYuning Chen
Yuning Chen
CWChunhe Wang
Chunhe Wang

16 June 2023 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
HLHua-Ying Li
Hua-Ying Li
YCYi-Li Chen
Yi-Li Chen
XDXiang-Nan Deng
Xiang-Nan Deng
HLHuan-Huan Li
Huan-Huan Li
JTJie Tan
Jie Tan
CWChunhe Wang
Chunhe Wang
Clinical application of PD-1 and PD-L1 monoclonal antibodies (mAbs) is hindered by their relatively low response rates and the occurrence of drug resistance. Co-expression of B7-H3 with PD-L1 has been found in various solid tumors, and combination therapies that target both PD-1/PD-L1 and B7-H3 pathways may provide additional therapeutic benefits. Up to today, however, no bispecific antibodies targeting both PD-1 and B7-H3 have reached the clinical development stage. In this study, we generated a stable B7-H3×PD-L1 bispecific antibody (BsAb) in IgG1-VHH format by coupling a humanized IgG1 mAb against PD-L1 with a humanized camelus variable domain of the heavy-chain of heavy-chain antibody (VHH) against human B7-H3. The BsAb exhibited favorable thermostability, efficient T cell activation, IFN-γ production, and antibody-dependent cell-mediated cytotoxicity (ADCC). In a PBMC humanized A375 xenogeneic tumor model, treatment with BsAb (10 mg/kg, i.p., twice a week for 6 weeks) showed enhanced antitumor activities compared to monotherapies and, to some degree, combination therapies. Our results suggest that targeting both PD-1 and B7-H3 with BsAbs increases their specificities to B7-H3 and PD-L1 double-positive tumors and induces a synergetic effect. We conclude that B7-H3×PD-L1 BsAb is favored over mAbs and possibly combination therapies in treating B7-H3 and PD-L1 double-positive tumors.

9 February 2022 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
JOJianxia Ou
Jianxia Ou
YZYanan Zhang
Yanan Zhang
YWYongmei Wang
Yongmei Wang
ZZZherui Zhang
Zherui Zhang
HWHongping Wei
Hongping Wei
CWChunhe Wang
Chunhe Wang